Gazulla J, Benavente I
Service of Neurology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Acta Neurol Scand. 2007 Oct;116(4):235-8. doi: 10.1111/j.1600-0404.2007.00912.x.
To preliminarily compare the efficacy of pregabalin with that of placebo on the cerebellar signs caused by cortical cerebellar atrophy (CCA). A deficiency of gamma-aminobutyric acid (GABA) has been described in the cerebellum in CCA, and pregabalin has been shown to enhance GABA release in rat hippocampus.
Two consecutive patients with clinical diagnoses of CCA took part in the study. A placebo and pregabalin, 225 mg per day, were administered in a single-blind scheme during 15 day periods to every patient; cerebellar function was evaluated with the Scale for the Assessment and Rating of Ataxia (SARA) at the end of each period. A video recording of the SARA items performed by the first patient accompanies this article.
Total SARA scores of 19 and 15 were obtained for the patients after placebo administration. The SARA scores decreased to 11 and 8, respectively, with the administration of pregabalin; an important amelioration of the ataxia was also evident. Both patients preferred continuing treatment with pregabalin when the trial was over.
Pregabalin was superior to placebo in the improvement of the cerebellar signs caused by CCA. Further studies are needed to confirm the present results.
初步比较普瑞巴林与安慰剂对皮质小脑萎缩（CCA）所致小脑体征的疗效。CCA患者的小脑已被证实存在γ-氨基丁酸（GABA）缺乏，且普瑞巴林已被证明可增强大鼠海马体中GABA的释放。
两名临床诊断为CCA的患者连续参与了该研究。采用单盲方案，每位患者在15天的周期内每日服用225毫克安慰剂和普瑞巴林；每个周期结束时，使用共济失调评估与评分量表（SARA）评估小脑功能。本文附带了第一位患者进行SARA项目的视频记录。
服用安慰剂后，两位患者的SARA总分分别为19分和15分。服用普瑞巴林后，SARA评分分别降至11分和8分；共济失调也有明显改善。试验结束时，两位患者均倾向于继续服用普瑞巴林进行治疗。
在改善CCA所致小脑体征方面，普瑞巴林优于安慰剂。需要进一步研究来证实目前的结果。
